Study of HS-20117 for advanced lung and other solid cancers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests HS-20117 to see if it is safe and how well it works in people with advanced solid tumors. You may qualify if your cancer has progressed after standard treatments (or you can’t tolerate them) and you can provide new or stored tumor tissue for testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old and have advanced solid tumor cancer that has progressed or you can’t tolerate standard treatment
- For lung cancer: have a specific EGFR mutation (either EGFR activating mutations or EGFR exon 20 insertion) depending on the study group
- Be able to provide fresh or stored tumor tissue for study testing
- Have at least one measurable tumor spot on scans and be well enough to do daily activities (ECOG 0–1)
- Agree to contraception rules during the study and have signed informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
This trial tests an investigational cell therapy called HS-IT201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if this treatment can help shrink tumors or slow their growth.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
This trial tests a new drug, HSK40118, for people with advanced non-small cell lung cancer (NSCLC) that has an EGFR mutation and has been treated with certain EGFR-targeted therapies before. The goal is to see if this drug can help when other treatments stop working.
This study tests a new drug called HS-20124 for people with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and how well it works.
This trial tests a new drug called HS-20122 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.